Literature DB >> 19194454

Persistence of herpes simplex virus DNA in cerebrospinal fluid of neonates with herpes simplex virus encephalitis.

A Mejías1, R Bustos, M I Ardura, C Ramírez, P J Sánchez.   

Abstract

OBJECTIVE: The significance of detecting herpes simplex virus (HSV) DNA in the cerebrospinal fluid (CSF) of infants with HSV encephalitis after receipt of prolonged therapy with high-dose (60 mg kg(-1) day(-1)) acyclovir is unknown. We report the clinical and laboratory characteristics, neuroimaging studies and outcomes of four neonates with HSV encephalitis who had persistence of CSF HSV DNA, by polymerase chain reaction (PCR) after 15 to 21 days of high-dose acyclovir therapy. STUDY
DESIGN: Retrospective chart review.
RESULTS: All four infants had abnormal neuroimaging studies and subsequently experienced severe developmental delay or death.
CONCLUSION: A persistently positive CSF HSV PCR in neonates may be another risk factor for worse neurodevelopmental outcome. Prospective studies are needed to document how often HSV DNA persists in CSF, elucidate whether it represents an initially high CSF viral load, ongoing viral replication or viral resistance, and determine its possible association with neurodevelopmental impairment.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19194454     DOI: 10.1038/jp.2008.235

Source DB:  PubMed          Journal:  J Perinatol        ISSN: 0743-8346            Impact factor:   2.521


  5 in total

Review 1.  Safety of alternative antiviral agents for neonatal herpes simplex virus encephalitis and disseminated infection.

Authors:  Yu Wang; Katherine P Smith
Journal:  J Pediatr Pharmacol Ther       Date:  2014-04

2.  Neonatal herpes encephalitis caused by a virologically confirmed acyclovir-resistant herpes simplex virus 1 strain.

Authors:  Satsuki Kakiuchi; Shigeaki Nonoyama; Hajime Wakamatsu; Kazuhiro Kogawa; Lixin Wang; Hitomi Kinoshita-Yamaguchi; Mutsuyo Takayama-Ito; Chang-Kweng Lim; Naoki Inoue; Masashi Mizuguchi; Takashi Igarashi; Masayuki Saijo
Journal:  J Clin Microbiol       Date:  2012-10-24       Impact factor: 5.948

3.  CMX001 potentiates the efficacy of acyclovir in herpes simplex virus infections.

Authors:  Mark N Prichard; Earl R Kern; Caroll B Hartline; E Randall Lanier; Debra C Quenelle
Journal:  Antimicrob Agents Chemother       Date:  2011-07-25       Impact factor: 5.191

4.  Neonatal herpes simplex fulminant hepatitis successfully treated with acyclovir.

Authors:  Said D Abuhasna; Zuhair M Shihab; Shaikha M Al Niyadi; Hossam M Tatari; Amer H Al Jundi; Khalid H Atwa
Journal:  J Clin Neonatol       Date:  2012-04

5.  Effectiveness of Early Antiviral Therapy in Disseminated Neonatal Herpes Simplex Virus 2 (HSV-2) with Fulminant Hepatic Failure.

Authors:  Divya Mirchandani; Rafia Jawed; Nayaab Khawar; Pramod Narula; Minnie John
Journal:  Am J Case Rep       Date:  2017-04-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.